Fibro Daily

Sub Q Actemra Treatment for Rheumatoid Arthritis Given Greenlight by FDA

Fibro Daily October 23, 2013

Adults suffering from rheumatoid arthritis who have not fully responded to treatment many soon have a new treatment option available to them. The FDA has approved a subcutaneous formulation of tocilizumab (Actemra), which has shown a 20% improvement based on the American College of Rheumatology criteria in 70% of patients.

Chief medical officer of the drug’s manufacturer has stated in a press release that the treatment can potentially prevent irreversible joint damage in patients with moderate to severely active rheumatoid arthritis.

Read more: FDA Greenlights Sub Q Actemra



Powered by Facebook Comments

Tagged with:

Leave a Comment

Login to your account

Can't remember your Password ?

Register for this site!